Mediwound (MDWD) AI Stock Analysis

• Market Cap: $230.53M
• Dividend Yield: N/A
• Average Volume (3M): 64.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: -1.41%
• EPS Growth: -22.05%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.23
• Shares Outstanding: 12,821,433
• 10 Day Avg. Volume: 40,331
• 30 Day Avg. Volume: 64,336
• PEG Ratio: -0.02
• Price to Book (P/B): 5.69
• Price to Sales (P/S): 8.77
• P/FCF Ratio: -8.91
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 9.38
• Enterprise Value/Gross Profit: 50.91
• Enterprise Value/Ebitda: -6.08
• 1Y Price Target: $30.00
• Price Target Upside: 64.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $18.50 ▲(1.54% Upside)

Mediwound's overall stock score reflects significant challenges in financial performance, particularly in profitability and cash flow management. However, the company shows potential for growth through strategic partnerships and clinical advancements. Technical indicators suggest a neutral trend with potential for upward movement. The earnings call provided positive guidance and strategic focus, but ongoing financial losses and valuation concerns weigh on the overall score.

Positive Factors

Strategic Partnerships

Partnerships with leading wound care companies enhance Mediwound's market reach and clinical trial support, strengthening its competitive position.

Revenue Growth

Strong revenue growth in the U.S. market indicates increasing adoption of NexoBrid, supporting long-term financial performance and market expansion.

Cash Position

A strong cash position offers Mediwound the ability to invest in key programs and navigate financial challenges, ensuring operational stability.

Negative Factors

Profitability Challenges

Ongoing net losses highlight profitability challenges, which may hinder long-term financial sustainability and require strategic cost management.

R&D and SG&A Expense Increases

Rising R&D and SG&A expenses pressure margins, impacting profitability and necessitating efficient resource allocation to sustain growth.

Operational Loss Increase

Higher operational losses reflect increased costs and slower revenue growth, challenging Mediwound's path to profitability and financial health.

Mediwound Business Overview & Revenue Model

Company Description

Mediwound Ltd. is a biopharmaceutical company focused on developing and commercializing innovative therapies for wound care and tissue regeneration. Primarily operating in the biotechnology sector, Mediwound specializes in advanced treatments for chronic and acute wounds, leveraging its proprietary product, NexoBrid, which is designed for the debridement of severe burns and other wounds. The company's mission is to improve patient outcomes through cutting-edge medical solutions that address critical unmet needs in wound management.

How the Company Makes Money

Mediwound generates revenue through the sale of its core products, primarily NexoBrid, which is marketed for the treatment of severe burns and other wounded tissues. The company also earns income from licensing agreements and collaborations with larger pharmaceutical firms, allowing it to expand its market reach and product offerings. Key revenue streams include direct sales to healthcare facilities, distribution agreements in various countries, and potential royalties from partners that utilize Mediwound's technology in their own product lines. Additionally, Mediwound may benefit from government grants and funding aimed at advancing medical innovations, further contributing to its financial performance.

Mediwound Financial Statement Overview

Summary

Mediwound's financial statements reflect growth potential but significant challenges in profitability and cash flow management. Revenue is growing, but margins are under pressure, and the company is not yet profitable. The balance sheet is stable with manageable leverage, but returns on equity are negative. Cash flow issues are a major concern, requiring strategic improvements to enhance financial health.

Income Statement

Mediwound's income statement shows a modest revenue growth rate of 3.36% TTM, indicating some positive momentum. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is relatively low at 18.43%, reflecting challenges in cost management. Overall, the income statement reflects a company with growth potential but significant profitability issues.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 0.40 TTM, suggesting manageable leverage levels. However, the return on equity is negative, indicating that the company is not generating sufficient returns on shareholders' equity. The equity ratio stands at 30.03%, showing a reasonable level of equity financing. Overall, the balance sheet is stable but highlights concerns about profitability and return generation.

Cash Flow

The cash flow statement indicates a significant challenge with negative operating cash flow and free cash flow. The free cash flow growth rate is positive at 86.9% TTM, but this is from a low base. The operating cash flow to net income ratio is negative, reflecting cash flow difficulties. Overall, the cash flow position is weak, with improvements needed in cash generation and management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.86M	20.22M	18.69M	26.50M	23.76M	21.76M
Gross Profit	3.66M	2.63M	3.58M	13.16M	8.77M	7.54M
EBITDA	-30.62M	-28.12M	-4.89M	-18.09M	-11.38M	-7.35M
Net Income	-28.23M	-30.22M	-6.72M	-19.60M	-13.55M	-9.20M
Balance Sheet
Total Assets	67.00M	73.50M	66.46M	50.02M	19.74M	31.07M
Cash, Cash Equivalents and Short-Term Investments	32.44M	43.16M	41.54M	33.90M	11.05M	21.58M
Total Debt	8.07M	6.93M	6.35M	846.00K	1.39M	1.74M
Total Liabilities	46.88M	42.34M	34.86M	39.10M	24.33M	23.80M
Stockholders Equity	20.12M	31.15M	31.59M	10.91M	-4.58M	7.27M
Cash Flow
Free Cash Flow	-19.27M	-19.90M	-16.93M	-12.44M	-9.40M	-7.82M
Operating Cash Flow	-15.26M	-13.62M	-10.46M	-11.88M	-8.92M	-6.89M
Investing Cash Flow	-7.90M	-8.40M	-34.32M	-481.00K	3.55M	17.39M
Financing Cash Flow	20.38M	19.39M	22.92M	35.76M	-1.05M	-629.00K

Mediwound Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.22
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDWD, the sentiment is Positive. The current price of 18.22 is below the 20-day moving average (MA) of 18.42, above the 50-day MA of 17.95, and below the 200-day MA of 18.38, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.25 is Neutral, neither overbought nor oversold. The STOCH value of 58.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MDWD.

Mediwound Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LCTX	54 Neutral	$411.04M	-9.86	-153.37%	―	24.05%	-169.73%
MDWD	52 Neutral	$230.53M	―	-148.65%	―	-1.41%	-22.05%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DSGN	47 Neutral	$355.36M	-5.58	-29.83%	―	―	-40.26%
VTYX	41 Neutral	$576.89M	-4.82	-45.35%	―	―	36.65%
ELDN	35 Underperform	$134.73M	―	-16.20%	―	―	―
TVGN	33 Underperform	$109.19M	-3.04	―	―	―	-406.67%

Mediwound Corporate Events

MediWound Raises $30 Million Through Share Offering to Boost EscharEx® Initiatives

On September 29, 2025, MediWound Ltd. entered into a securities purchase agreement for the sale of 1,734,105 ordinary shares at $17.30 per share, generating approximately $30 million in gross proceeds. The offering closed on September 30, 2025, and the funds are intended to support the pre-commercial activities of EscharEx®, enhance manufacturing capabilities, and for general corporate purposes. H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a transaction fee and additional allowances. This financial move is expected to bolster MediWound’s operational capacity and market positioning in the biotechnology sector.

MediWound Announces $30 Million Direct Offering to Boost Operations

On September 29, 2025, MediWound Ltd. announced a $30 million registered direct offering of ordinary shares, led by a U.S.-based mutual fund and other healthcare investors. The offering, expected to close on or about September 30, 2025, aims to support the pre-commercial activities of EscharEx, enhance manufacturing capabilities, and fund general corporate purposes, potentially strengthening MediWound’s market position and operational capacity.

MediWound Executives Purchase Shares, Signaling Confidence

On August 18, 2025, MediWound Ltd. announced that its Chairman, Mr. Nachum (Homi) Shamir, and CEO, Mr. Ofer Gonen, purchased a total of 11,200 ordinary shares of the company in open market transactions. These purchases, made at an average price of $17.74 per share, were conducted in accordance with the company’s insider trading policy, reflecting confidence in the company’s future prospects and potentially influencing stakeholder perceptions positively.

MediWound Reports Q2 2025 Financial Results and Strategic Updates

On August 14, 2025, MediWound Ltd. announced its financial results for the second quarter of 2025, reporting a 43% increase in revenue from the prior quarter, reaching $5.7 million. The company highlighted ongoing patient enrollment in its VALUE Phase III trial for EscharEx, strategic collaborations with Essity and Convatec, and manufacturing expansion for NexoBrid, which is expected to reach full operational capacity by the end of 2025. Despite a net loss of $13.3 million, MediWound’s financial performance showed improved gross profit margins and increased R&D investments, reflecting confidence in its long-term strategy.